Recently, the team of Chief Physician Lu Jinsong of Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine proposed and established a new family history score (NeoFHS) system for the first time, and found that it can be used as a new method for predicting the sensitivity of neoadjuvant platinum-containing chemotherapy.
International clinical trials have shown that platinum drug sensitivity is related to homologous recombination defects (HRD), especially BRCA1/2 mutations
Research data shows that NeoFHS can be used as a new practical and effective biomarker, which is better than the traditional and classic family history scoring systems recommended by the United States Preventive Services Working Group (including Ontario score, Manchester score and Pedigree score) Predictive and prognostic capabilities
Lu Jinsong said that the system needs to be further verified through prospective, large-sample clinical trials in the future
Related paper information: https://doi.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
